Stable bone density in HAART-treated individuals with HIV: A meta-analysis

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 9, 2011, Pages 2721-2723

  Bolland, Mark J ^a   Wang, Tom K M ^a   Grey, Andrew ^a   Gamble, Greg D ^a   Reid, Ian R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DENSITOMETRY; DISEASE DURATION; DRUG SAFETY; FEMALE; FEMUR NECK; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDE EFFECT; SPINE; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DENSITY; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; OSTEOPOROSIS;

EID: 80052531222     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-0591     Document Type: Article

References (60)

1. Brown T.T., Qaqish R.B. 2006 Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review. AIDS 20:2165-2174 (Pubitemid 44684707)
2. Bolland M.J., Grey A.B., Gamble G.D., Reid I.R. 2007 Low body weight mediates the relationship between HIV infection and low bone mineral density: A meta-analysis. J Clin Endocrinol Metab 92:4522-4528
3. Nolan D., Upton R., McKinnon E., John M., James I., Adler B., Roff G., Vasikaran S., Mallal S. 2001 Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 15:1275-1280 (Pubitemid 32592360)
4. Mondy K., Yarasheski K., Powderly W.G., Whyte M., Claxton S, De-Marco D, Hoffmann M, Tebas P 2003 Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36:482-490
5. Gallant J.E., Staszewski S., Pozniak A.L., DeJesus E., Suleiman J.M., Miller M.D., Coakley D.F., Lu B., Toole J.J., Cheng A.K. 2004 Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 292: 191-201 (Pubitemid 38917996)
6. Bolland M.J., Grey A.B., Horne A.M., Briggs S.E., Thomas MG, Ellis-Pegler RB, Woodhouse AF, Gamble GD, Reid IR 2007 Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years. Clin Endocrinol (Oxf) 67:270-275
7. Duvivier C., Kolta S., Assoumou L., Ghosn J., Rozenberg S., Murphy R.L., Katlama C., Costagliola D. 2009 Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 27:817-824
8. Van Vonderen M.G., Lips P., Van Agtmael M.A., Hassink E.A., Brinkman K., Geerlings S.E., Sutinen J., Ristola M., Danner S.A., Reiss P. 2009 First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 23:1367-1376
9. Bolland M.J., Grey A.B., Horne A.M., Briggs S.E., Thomas MG, Ellis-Pegler RB, Woodhouse AF, Gamble GD, Reid IR 2006 Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy. Clin Endocrinol (Oxf) 65:191-197
10. Hannan M.T., Felson D.T., Dawson-Hughes B., Tucker K.L., Cupples L.A., Wilson P.W., Kiel D.P. 2000 Risk factors for longitudinal bone loss in elderly men and women: The Framingham Osteoporosis Study. J Bone Miner Res 15:710-720 (Pubitemid 30174025)
11. Wu F., Ames R., Clearwater J., Evans M.C., Gamble G., Reid I.R. 2002 Prospective 10-year study of the determinants of bone density and bone loss in normal postmenopausal women, including the effect of hormone replacement therapy. Clin Endocrinol (Oxf) 56:703-711
12. Reid I.R. 2002 Relationships among body mass, its components, and bone. Bone 31:547-555 (Pubitemid 35449695)
13. Hozo S.P., Djulbegovic B., Hozo I. 2005 Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13
14. Higgins J.P., Deeks J.J., Altman D.J. 2008 Special topics in statistics. In: Higgins JP, Green S, eds. Cochrane handbook for systematic reviews of interventions. Chichester, UK: John Wiley and Sons; 481-530
15. Dolan S.E., Kanter J.R., Grinspoon S. 2006 Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 91:2938-2945 (Pubitemid 44271739)
16. Sharma A., Cohen H., Freeman R., Santoro N., Schoenbaum E, Prospective evaluation of bone mineral density among middle-aged HIV-infected and -uninfected women. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 2009 (Abstract 757)
17. Yin M., McMahon D., Shu A., Zhang C., Ferris D., Colon I., Rogers H., Shane E. 2009 Determinants of bone loss in HIV- postmenopausal women. J Bone Miner Res 24:S362-S363
18. Sharma A., Flom P.L., Weedon J., Klein R.S. 2010 Prospective study of bone mineral density changes in aging men with or at risk for HIV infection. AIDS 24:2337-2345
19. Yin M.T., Lu D., Cremers S., Tien P.C., Cohen M.H., Shi Q., Shane E., Golub E.T., Anastos K. 2010 Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr 53:202-208
20. Pazianas M., Macallan D.C., Zaidi M., Griffin G.E. 1993 Bone mineral density in HIV infection and the acquired immune deficiency syndrome: A longitudinal study. J Bone Miner Res 8:S285-S285 (Abstract)
21. Paton N.I., Macallan D.C., Griffin G.E., Pazianas M. 1997 Bone mineral density in patients with human immunodeficiency virus infection. Calcif Tissue Int 61:30-32 (Pubitemid 27262397)
22. Tsekes G., Chrysos G., Douskas G., Paraskeva D., Mangafas N., Giannakopoulos D., Papanikolaou M., Georgiou E., Lazanas M.C. 2002 Body composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors. HIV Med 3:85-90 (Pubitemid 34567578)
23. Cirelli A., Cirelli G., Balsamo G., Masciangelo R., Stasolla A., Marini M. 2003 Body habitus changes, metabolic abnormalities, osteopenia and cardiovascular risk in patients treated for human immunodeficiency virus infection. Ann Ital Med Int 18:238-245
24. Fernández-Rivera J., García R., Lozano F., Macías J., García-García J.A., Mira J.A., Corzo JE, Gómez-Mateos J, Rueda A, Sánchez-Burson J, Pineda JA 2003 Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials 4:337-346
25. Guaraldi G., Orlando G., Madeddu G., Vescini F., Ventura P., Campostrini S., Mura M.S., Parise N., Caudarella R., Esposito R. 2004 Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials 5:269-277 (Pubitemid 39545399)
26. Madeddu G., Spanu A., Solinas P., Calia G.M., Lovigu C., Chessa F., Mannazzu M., Falchi A., Mura M.S., Madeddu G. 2004 Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 48:39-48 (Pubitemid 39069663)
27. Tebas P., Yarasheski K., Henry K., Claxton S., Kane E., Bordenave B., Klebert M., Powderly W.G. 2004 Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses 20:589-594 (Pubitemid 38813655)
28. Mondy K., Powderly W.G., Claxton S.A., Yarasheski K.H., Royal M., Stoneman J.S., Hoffmann M.E., Tebas P. 2005 Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 38: 426-431 (Pubitemid 40381552)
29. Bolland M.J., Grey A.B., Horne A.M., Briggs S.E., Thomas MG, Ellis-Pegler RB, Woodhouse AF, Gamble GD, Reid IR 2007 Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab 92:1283-1288
30. Briot K., Kolta S., Flandre P., Boue F., Van P.N., Cohen-Codar I., Salbert F.E., Chauvin J.P., Norton M., Delfraissy J.F., Roux C. 2007 One-year bone mineral density changes in antiretroviral-naive HIV-infected patients treated by a triple, versus a single-agent regimen, with Lopinavir/ ritonavir in the Monark Trial. Antiviral Ther 12:L62-L63 (Abstract)
31. Cassetti I., Madruga J.V., Suleiman J.M., Etzel A., Zhong L., Cheng A.K., Enejosa J. 2007 The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 8:164-172 (Pubitemid 47121761)
32. McComsey G.A., Kendall M.A., Tebas P., Swindells S., Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA 2007 Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 21:2473-2482
33. Tebas P., Zhang J., Yarasheski K., Evans S., Fischl M.A., Shevitz A., Feinberg J., Collier A.C., Shikuma C., Brizz B., Sattler F. 2007 Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: Results of a prospective randomized trial (AIDS clinical trial group 5125s). J Acquir Immune Defic Syndr 45:193-200
34. Bolland M.J., Grey A.B., Horne A.M., Briggs S.E., Thomas MG, Ellis-Pegler RB, Callon KE, Gamble GD, Reid IR 2008 Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months. J Bone Miner Res 23:1304-1308
35. Jacobson D.L., Spiegelman D., Knox T.K., Wilson I.B. 2008 Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr 49:298-308
36. McComsey G.A., Lo Re 3rd V., O'Riordan M., Walker U.A., Lebrecht D., Baron E., Mounzer K., Frank I. 2008 Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: A randomized, controlled study. Clin Infect Dis 46:1290-1296 (Pubitemid 351589916)
37. Rivas P., Górgolas M., García-Delgado R., Díaz-Curiel M., Goyenechea A., Fernández-Guerrero M.L. 2008 Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir. HIV Med 9:89-95 (Pubitemid 351228131)
38. Van den Bout-van den Beukel C.J., Van den Bos M., Oyen W.J., Hermus A.R., Sweep F.C., Tack C.J., Bosch M.E., BurgerD.M.,Koopmans P.P., Van der Ven A.J. 2008 The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D-deficient HIV-1-infected patients. HIV Med 9:771-779
39. Brown T.T., McComsey G.A., King M.S., Qaqish R.B., Bernstein B.M., Da Silva B.A. 2009 Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 51:554-561
40. Dolan Looby S.E., Collins M., Lee H., Grinspoon S. 2009 Effects of long-term testosterone administration in HIV-infected women: A randomized, placebo-controlled trial. AIDS 23:951-959
41. Huang J., Meixner L., Fernandez S., McCutchan J.A. 2009 A doubleblinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS 23:51-57
42. Madeddu G., Spanu A., Chessa F., Calia G.M., Lovigu C., Mannazzu M., Falchi A., Sanna D., Mura M.S., Madeddu G. 2009 Serum leptin and bone metabolism in HIV patients treated with highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 53:290-301
43. Degris E., Delpierre C., Sommet A., Sire S., Lassoued S., Aquilina C., Marchou B., Massip P., Obadia M., Marion-Latard F., Bonnet E., Bernard J. 2010 Longitudinal study of body composition of 101 HIV men with lipodystrophy: Dual-energy x-ray criteria for lipodystrophy evolution. J Clin Densitom 13:237-244
44. Hansen A.B., Obel N., Nielsen H., Pedersen C., Gerstoft J. 2011 Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: Data from a randomized trial. HIV Med 12: 157-165
45. McComsey G, O'RiordanMA,Choi J, Libutti D, Rowe D, Storer N, Harrill D, Everhart T, Cheung P, Gerschenson M, A 48-week randomized study of uridine supplementation vs switch to tenofovir (TDF) on limb fat, mitochondrial function, inflammation, and bone mineral density in HIV lipoatrophy. 17th Conference of Retrovirus and Opportunistic Infections, San Francisco, CA, 2010 (Abstract 723)
46. Stellbrink H.J., Orkin C., Arribas J.R., Compston J., Gerstoft J., Van Wijngaerden E., Lazzarin A., Rizzardini G., Sprenger H.G., Lambert J., Sture G., Leather D., Hughes S., Zucchi P., Pearce H. 2010 Comparison of changes in bone density and turnover with abacavirlamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 51:963-972
47. Tungsiripat M., Bejjani D.E., Rizk N, O'riordan MA, Ross AC, Hileman C, Storer N, Harrill D, McComsey GA 2010 Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens. AIDS 24:1291-1298
48. Villareal D.T., Fontana L., Weiss E.P., Racette S.B., Steger-May K., Schechtman K.B., Klein S., Holloszy J.O. 2006 Bone mineral density response to caloric restriction-induced weight loss or exercise-induced weight loss: A randomized controlled trial. Archives of internal medicine 166:2502-2510 (Pubitemid 44913236)
49. Borderi M., Gibellini D., Vescini F., De Crignis E., Cimatti L., Biagetti C., Tampellini L., Re M.C. 2009 Metabolic bone disease in HIV infection. AIDS 23:1297-1310
50. + adults: report of three cases and literature review. J Bone Miner Res 19:714-721
51. Grund B., Peng G., Gibert C.L., Hoy J.F., Isaksson R.L., Shlay J.C., Martinez E., Reiss P., Visnegarwala F., Carr A.D. 2009 Continuous antiretroviral therapy decreases bone mineral density. AIDS 23:1519-1529
52. Arnsten J.H., Freeman R., Howard A.A., Floris-Moore M., Lo Y., Klein R.S. 2007 Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 21:617-623
53. Yin M.T., Shi Q., Hoover D.R., Anastos K., Sharma A., Young M., Levine A., Cohen M.H., Shane E., Golub E.T., Tien P.C. 2010 Fracture incidence in HIV-infected women: Results from the Women's Interagency HIV Study. AIDS 24:2679-2686
54. Collin F., Duval X., Le Moing V., Piroth L., Al Kaied F., Massip P., Villes V., ChêneG., Raffi F. 2009 Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS 23: 1021-1024
55. Prior J., Burdge D., Maan E., Milner R., Hankins C., Klein M., Walmsley S. 2007 Fragility fractures and bone mineral density in HIV positive women: A case-control population-based study. Osteoporos Int 18:1345-1353 (Pubitemid 47389474)
56. Triant V.A., Brown T.T., Lee H., Grinspoon S.K. 2008 Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 93:3499-3504
57. Womack J., Goulet J., Gibert C., Brandt C., Mattocks K., Rimland D., Rodriguez-Barradas M., Tate J., Yin M., Amy J; Veterans Aging Cohort Project Team, HIV infection and fragility fracture risk among male veterans. 17th Conference of Retrovirus and Opportunistic Infections, San Francisco, CA, 2010 (Abstract 129)
58. McComsey G.A., Tebas P., Shane E., Yin M.T., Overton E.T., Huang J.S., Aldrovandi G.M., Cardoso S.W., Santana J.L., Brown T.T. 2010 Bone disease in HIV infection: A practical review and recommendations for HIV care providers. Clin Infect Dis 51:937-946
59. American Association of Clinical Endocrinologists 2003 Medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis. Endocr Pract 9:544-564
60. Dawson-Hughes B. 2008 A revised clinician's guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab 93:2463-2465 (Pubitemid 352008504)